This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrahim, A. S.
Right arrow Articles by Edwards, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrahim, A. S.
Right arrow Articles by Edwards, J. E., Jr.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2003, p. 3343-3344, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3343-3344.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae

Ashraf S. Ibrahim,1,2* Valentina Avanessian,1 Brad Spellberg,1 and John E. Edwards Jr.1,2

Harbor-UCLA Research and Education Institute, Torrance, California 90502,1 UCLA School of Medicine, Los Angeles, California 900242

Received 3 July 2003/ Returned for modification 4 July 2003/ Accepted 8 July 2003

The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice (P = 0.001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.

* Corresponding author. Mailing address: Division of Infectious Diseases, St. John's Cardiovascular Research Center, Harbor-UCLA Research and Education Institute, Bldg. RB2, 1124 West Carson St., Torrance, CA 90502. Phone: (310) 222-3813. Fax: (310) 782-2016. E-mail: Ibrahim{at}HUMC.EDU.

Antimicrobial Agents and Chemotherapy, October 2003, p. 3343-3344, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3343-3344.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez, M. M., Calvo, E., Marine, M., Pastor, F. J., Fernandez-Ballart, J., Guarro, J. (2009). Efficacy of Liposomal Amphotericin B Combined with Gamma Interferon or Granulocyte-Macrophage Colony-Stimulating Factor for Treatment of Systemic Zygomycosis in Mice. Antimicrob. Agents Chemother. 53: 3569-3571 [Abstract] [Full Text]  
  • Ibrahim, A. S., Gebremariam, T., Schwartz, J. A., Edwards, J. E. Jr., Spellberg, B. (2009). Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis. Antimicrob. Agents Chemother. 53: 772-775 [Abstract] [Full Text]  
  • Ibrahim, A. S., Gebremariam, T., Fu, Y., Edwards, J. E. Jr., Spellberg, B. (2008). Combination Echinocandin-Polyene Treatment of Murine Mucormycosis. Antimicrob. Agents Chemother. 52: 1556-1558 [Abstract] [Full Text]  
  • Ibrahim, A. S., Gebremariam, T., Husseiny, M. I., Stevens, D. A., Fu, Y., Edwards, J. E. Jr., Spellberg, B. (2008). Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis. Antimicrob. Agents Chemother. 52: 1573-1576 [Abstract] [Full Text]  
  • Olson, J. A., Adler-Moore, J. P., Jensen, G. M., Schwartz, J., Dignani, M. C., Proffitt, R. T. (2008). Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products. Antimicrob. Agents Chemother. 52: 259-268 [Abstract] [Full Text]  
  • Ibrahim, A. S., Edwards, J. E. Jr, Fu, Y., Spellberg, B. (2006). Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 58: 1070-1073 [Abstract] [Full Text]  
  • Spellberg, B., Edwards, J. Jr., Ibrahim, A. (2005). Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin. Microbiol. Rev. 18: 556-569 [Abstract] [Full Text]  
  • Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E. Jr., Douglas, C. M. (2005). Caspofungin Inhibits Rhizopus oryzae 1,3-{beta}-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. Antimicrob. Agents Chemother. 49: 721-727 [Abstract] [Full Text]  
  • Spellberg, B., Fu, Y., Edwards, J. E. Jr., Ibrahim, A. S. (2005). Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice. Antimicrob. Agents Chemother. 49: 830-832 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»